CD274 and non-small cell lung carcinoma: A phase II trial, EMPOWERVAX Lung 1, is currently recruiting advanced NSCLC patients with greater than or equal to 50% PD-L1 expression on tumor cells to receive BNT116 in combination with the anti-PD1 mAb, cemiplimab, or cempilimab alone (NCT05557591) [169].